Proposed Common Stock Public Offering, Cytori Therapeutics (CYTX)
CYTX (10/7/10) intends to offer and sell shares of its common stock in an underwritten public offering.
The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- Jefferies & Company, Inc. is acting as sole book-running manager for the offering.
The securities described above are being offered by Cytori pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (“SEC”) on 2/11/09.
- A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov;
- Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Equity Syndicate Prospectus Department, Jefferies & Company, 520 Madison Avenue, 12th Floor, New York, NY, 10022, at 877-547-6340, and at Prospectus_Department@Jefferies.com.
Categories: Stem Cell Technology
